{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tildrakizumab", "query": { "intervention": "Tildrakizumab" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 20, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tildrakizumab&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T23:04:15.168Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02980705", "title": "Efficacy and Safety Study of SUNPG1622", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Active Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis" ], "interventions": [ { "name": "SUNPG1622 I dose", "type": "DRUG" }, { "name": "Placebo dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sun Pharmaceutical Industries Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2017-11-06", "completion_date": "2019-09-03", "has_results": true, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-09-03T23:04:15.168Z", "location_count": 1, "location_summary": "Middleburg Heights, Ohio", "locations": [ { "city": "Middleburg Heights", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02980705" }, { "nct_id": "NCT07352566", "title": "Utilization of a Microdevice for Psoriasis and Atopic Dermatitis", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Psoriasis", "Atopic Dermatitis" ], "interventions": [ { "name": "In situ cutaneous microdevice", "type": "DEVICE" }, { "name": "Triamcinolone", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Calcipotriene", "type": "DRUG" }, { "name": "Tapinarof", "type": "DRUG" }, { "name": "Crisaborole", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Certolizumab", "type": "DRUG" }, { "name": "Infliximab", "type": "DRUG" }, { "name": "Secukinumab", "type": "DRUG" }, { "name": "Ixekizumab", "type": "DRUG" }, { "name": "Apremilast", "type": "DRUG" }, { "name": "Risankizumab", "type": "DRUG" }, { "name": "Ustekinumab", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Mycophenolate", "type": "DRUG" }, { "name": "Azathioprine", "type": "DRUG" }, { "name": "Chloroquine", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Tofacitinib", "type": "DRUG" }, { "name": "Deucravacitinib", "type": "DRUG" }, { "name": "Dupilumab", "type": "DRUG" }, { "name": "Tralokinumab", "type": "DRUG" }, { "name": "Guselkumab", "type": "DRUG" }, { "name": "Tildrakizumab", "type": "DRUG" }, { "name": "Baractinib", "type": "DRUG" }, { "name": "Abrocitinib", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Lebrikizumab", "type": "DRUG" }, { "name": "Nemolizumab", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Bimekizumab", "type": "DRUG" }, { "name": "Roflumilast", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2026-08-01", "completion_date": "2030-06-01", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-09-03T23:04:15.168Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07352566" }, { "nct_id": "NCT06399432", "title": "Mediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms of Psoriasis in Patients Treated With Anti-IL-17 or Anti-IL-23 Inhibitors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Mediterranean Diet", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University Hospitals Cleveland Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "94 Years", "sex": "ALL", "summary": "18 Years to 94 Years" }, "enrollment_count": 36, "start_date": "2022-10-18", "completion_date": "2026-07-01", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-09-03T23:04:15.168Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06399432" }, { "nct_id": "NCT04271540", "title": "MIcrovascular dysfuNction In Moderate-severe Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Psoriasis", "Cardiovascular Disease" ], "interventions": [ { "name": "Tildrakizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Marcelo F. Di Carli, MD, FACC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 36, "start_date": "2020-04-04", "completion_date": "2024-07-17", "has_results": true, "last_update_posted_date": "2025-11-25", "last_synced_at": "2026-09-03T23:04:15.168Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04271540" }, { "nct_id": "NCT05390515", "title": "Psoriatic Immune Response to Tildrakizumab", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Psoriasis Vulgaris" ], "interventions": [ { "name": "Tildrakizumab Prefilled Syringe", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 10, "start_date": "2022-09-01", "completion_date": "2028-09-01", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-09-03T23:04:15.168Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05390515" }, { "nct_id": "NCT04541329", "title": "Predicting Inflammatory Skin Disease Response to IL-23 Blockade", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Psoriasis Vulgaris" ], "interventions": [ { "name": "Tildrakizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2020-09-16", "completion_date": "2023-01-15", "has_results": true, "last_update_posted_date": "2024-04-30", "last_synced_at": "2026-09-03T23:04:15.168Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04541329" }, { "nct_id": "NCT03897075", "title": "Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Plaque Psoriasis", "Moderate to Severe Nail Psoriasis" ], "interventions": [ { "name": "Tildrakizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sun Pharmaceutical Industries Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 99, "start_date": "2021-05-13", "completion_date": "2025-01-30", "has_results": true, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-09-03T23:04:15.168Z", "location_count": 11, "location_summary": "Encinitas, California • Fountain Valley, California • Los Angeles, California + 8 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Coral Gables", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03897075" }, { "nct_id": "NCT02980692", "title": "Efficacy and Safety Study of SUNPG1623", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Active Psoriatic Arthritis" ], "interventions": [ { "name": "SUNPG1623 I", "type": "DRUG" }, { "name": "SUNPG1623 II", "type": "DRUG" }, { "name": "SUNPG1623 III", "type": "DRUG" }, { "name": "SUNPG1623 IV", "type": "DRUG" }, { "name": "PLACEBO", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sun Pharmaceutical Industries Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 391, "start_date": "2017-04-19", "completion_date": "2019-09-24", "has_results": true, "last_update_posted_date": "2023-01-27", "last_synced_at": "2026-09-03T23:04:15.168Z", "location_count": 1, "location_summary": "Middleburg Heights, Ohio", "locations": [ { "city": "Middleburg Heights", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02980692" }, { "nct_id": "NCT04991116", "title": "Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriatic Arthritis" ], "interventions": [ { "name": "TILD sub-cutaneous (SC) injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sun Pharmaceutical Industries Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 529, "start_date": "2022-06-30", "completion_date": "2029-04", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-09-03T23:04:15.168Z", "location_count": 41, "location_summary": "Dothan, Alabama • Gilbert, Arizona • Mesa, Arizona + 36 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Covina", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04991116" }, { "nct_id": "NCT05110313", "title": "Effects of Tildrakizumab on Epigenetic Age", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Psoriasis", "Aging", "Epigenetic Disorder", "Inflammation; Skin" ], "interventions": [ { "name": "TILDRAKIZUMAB", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Carlos Wambier", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "35 Years", "maximum_age": null, "sex": "ALL", "summary": "35 Years and older" }, "enrollment_count": 30, "start_date": "2022-04-08", "completion_date": "2024-05-27", "has_results": false, "last_update_posted_date": "2024-07-18", "last_synced_at": "2026-09-03T23:04:15.168Z", "location_count": 1, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT05110313" } ] }